CA3034956C - TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE - Google Patents

TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE

Info

Publication number
CA3034956C
CA3034956C CA3034956A CA3034956A CA3034956C CA 3034956 C CA3034956 C CA 3034956C CA 3034956 A CA3034956 A CA 3034956A CA 3034956 A CA3034956 A CA 3034956A CA 3034956 C CA3034956 C CA 3034956C
Authority
CA
Canada
Prior art keywords
compound
dose
administering
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3034956A
Other languages
English (en)
French (fr)
Other versions
CA3034956A1 (en
Inventor
Guido Hanauer
Hiroshi Nagabukuro
Yuichiro Amano
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA3034956A1 publication Critical patent/CA3034956A1/en
Application granted granted Critical
Publication of CA3034956C publication Critical patent/CA3034956C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3034956A 2016-08-26 2017-08-25 TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE Active CA3034956C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380004P 2016-08-26 2016-08-26
US62/380,004 2016-08-26
PCT/EP2017/071418 WO2018037109A1 (en) 2016-08-26 2017-08-25 Treatment of nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CA3034956A1 CA3034956A1 (en) 2018-03-01
CA3034956C true CA3034956C (en) 2024-10-29

Family

ID=59699703

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3034956A Active CA3034956C (en) 2016-08-26 2017-08-25 TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE

Country Status (7)

Country Link
US (1) US11179384B2 (cg-RX-API-DMAC7.html)
EP (1) EP3503892A1 (cg-RX-API-DMAC7.html)
JP (1) JP7048863B2 (cg-RX-API-DMAC7.html)
CN (1) CN110099686B (cg-RX-API-DMAC7.html)
AU (1) AU2017317575B2 (cg-RX-API-DMAC7.html)
CA (1) CA3034956C (cg-RX-API-DMAC7.html)
WO (1) WO2018037109A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001238288A1 (en) 2000-02-16 2001-08-27 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
RS53543B1 (sr) * 2004-03-03 2015-02-27 Takeda Gmbh Novi hidroksi-6-heteroarilfenantridini i njihova primena kao pde4 inhibitori
CN101133045A (zh) * 2005-03-02 2008-02-27 尼科梅德有限责任公司 6-杂环基取代的六氢菲啶衍生物的新盐类
KR101421914B1 (ko) 2005-03-02 2014-07-22 다케다 게엠베하 6-헤테로시클릴 치환된 헥사히드로페난트리딘 유도체의 신규한 염
NZ574710A (en) * 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP3096760A1 (en) * 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
ES2749433T3 (es) * 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
EP3328381A1 (en) * 2015-07-29 2018-06-06 Takeda GmbH Pde4 inhibitor for the treatment of diabetic nephropathy

Also Published As

Publication number Publication date
US11179384B2 (en) 2021-11-23
CN110099686B (zh) 2022-04-15
JP2019524860A (ja) 2019-09-05
WO2018037109A1 (en) 2018-03-01
EP3503892A1 (en) 2019-07-03
CN110099686A (zh) 2019-08-06
CA3034956A1 (en) 2018-03-01
AU2017317575A1 (en) 2019-03-28
US20210283122A1 (en) 2021-09-16
JP7048863B2 (ja) 2022-04-06
AU2017317575B2 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
US20220313677A1 (en) Methods for treating liver disorders using fxr agonists
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
KR20170095302A (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
KR20190044667A (ko) Fxr 작용제의 신규 요법
AU2015231076B2 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
CN114096257A (zh) 包含如sglt 1/2抑制剂的sglt抑制剂的治疗
US20240277745A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
US10836757B1 (en) Polymorphic forms of metopimazine
US20220313622A1 (en) Phytocannabinoids for preventing or treating non-alcoholic fatty liver disease, dyslipidemia, and type 2 diabetes
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
US20090298796A1 (en) Reducing risk of type 2 diabetes (t2d)
WO2019106550A1 (en) Fxr agonists for the treatment of liver diseases
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
EP4166137B1 (en) Therapeutic agent for fatty liver disease
TWI906348B (zh) 脂肪性肝疾病之治療劑
HK40080642A (en) Therapeutic agent for fatty liver disease
HK40089150B (en) Therapeutic agent for fatty liver disease
CN120771133A (zh) 原发性胆汁性胆管炎的长期治疗
HK1257647B (en) Methods for using fxr agonists
JP2011032267A (ja) １１βＨＳＤ１阻害剤およびその用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325